AMENDMENT TO EMPLOYMENT AGREEMENT - DAVID TUCKEmployment Agreement • March 9th, 2017 • Curis Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT (the “Amendment”) is made as of March 7, 2017 between Curis, Inc., a Delaware corporation (the “Company”), and David Tuck, M.D. (the “Employee”).
AMENDMENT TO EMPLOYMENT AGREEMENT - ALI FATTAEYEmployment Agreement • March 9th, 2017 • Curis Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT (the “Amendment”) is made as of March 7, 2017 between Curis, Inc., a Delaware corporation (the “Company”), and Ali Fattaey, Ph.D. (the “Employee”).
Re: Collaborative Research, Development and License Agreement: Consent and Payment DirectionCuris Inc • March 9th, 2017 • Biological products, (no disgnostic substances)
As we have discussed, Curis, Inc., a Delaware corporation (“Curis”), is in the process of discussing, under confidentiality agreements, a potential refinancing of the existing debt financing (the “Transaction”) of Curis Royalty LLC, a wholly owned subsidiary of Curis (the “Borrower”) by HealthCare Royalty Partners III, L.P. (the “Investor”), where the debt would be secured by the Borrower’s rights to receive certain payments under that certain Collaborative Research, Development and License Agreement, dated as of June 11, 2003, by and between Curis and Genentech, Inc. (“Genentech”), as amended as of December 10, 2004, April 11, 2005, May 8, 2006 and again as of April 26, 2012 (the “License Agreement”). As noted below, you have previously consented to the assignment of certain payment rights under the License Agreement from Curis to the Borrower. In connection with the Transaction, by this letter agreement (“Letter Agreement”), Curis is seeking Genentech’s consent under Section 16.8 of
AMENDMENT TO EMPLOYMENT AGREEMENT - JAMES DENTZEREmployment Agreement • March 9th, 2017 • Curis Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT (the “Amendment”) is made as of March 7, 2017 between Curis, Inc., a Delaware corporation (the “Company”), and James E. Dentzer (the “Employee”).
CREDIT AGREEMENT Dated as of March 6, 2017Credit Agreement • March 9th, 2017 • Curis Inc • Biological products, (no disgnostic substances) • New York
LIMITED RECOURSE PLEDGE AGREEMENT, dated as of [_____], 2017, made by Curis, Inc. (the “Grantor”), in favor of HealthCare Royalty Partners III, L.P. (the “Lender”). Any capitalized term utilized herein shall have the meaning as specified in the Credit Agreement (defined below), unless such term is otherwise specifically defined herein.
